iidp.coh.orgIslet Isolation Development Program

Contact Us : [email protected] Apply Now! Overview Program History Meet our Team Consultants Program Statistics Program Sponsor Announcements Mission Statement Newsletters Logos Centers Islet Isolation Center Contact Information Frequently Asked Questions Policies & Standard Operating Procedures Center Login Investigators Our Services Islet Award Initiative Research Data Repository Frequently Asked Questions Policies & Standard Operating Procedures Investigator Login Helpful Hints for Human Islets Publications Funding Contact Us X Apply Now! Overview Program History Meet our Team Consultants Program Statistics Program Sponsor Announcements Mission Statement Newsletters Logos Centers Islet Isolation Center Contact Information Frequently Asked Questions Policies & Standard Operating Procedures Center Login Investigators Our Services Islet Award Initiative Research Data Repository Frequently Asked Questions Policies & Standard Operating Procedures Investigator Login Helpful Hints for Human Islets Publications Funding Contact Us GO [Updated June 2020] Out of caution for the ongoing COVID-19 pandemic, all human tissue distributions facilitated by the IIDP require COVID-19 testing and confirmed negative results for all donors. All processing center staff will use OSHA’s Universal Precautions while handling tissue, and it’s advised that all tissue recipients do the same.Integrated Islet Distribution Program Providing high quality human islets to the diabetes research community, including international and corporate researchers. Supported by the Special Statutory Funding Program for Type 1 Diabetes Research Administered by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) - National Institutes of HealthNextApply for a study to receive islets, tissue and data Apply Now! Apply for a study to receive islets, tissue and dataClick here to preview information that will be required for an IIDP application and to download the Letter of Agreement and Biosketch forms. View our Investigator Brochure for detailed program and pricing information. Supported by the Special Statutory Funding Program for Type 1 Diabetes Research Administered by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) - National Institutes of HealthOur Mission The goal of the Integrated Islet Distribution Program (IIDP) is to work with the leading islet isolation centers in the U.S. to distribute high quality human islets, associated tissues, and complementary data to the diabetes research community, in order to advance scientific discoveries and translational medicine. to the diabetes research community, in order to advance scientific discoveries and translational medicine.General Information Overview Overview of the program The Integrated Islet Distribution Program (IIDP) began at City of Hope (COH) as the Islet Cell Resource in 2002, and has been operating as the IIDP since 2009, as the largest organized effort in the world to provide human islet preparations for research. Because human islet research is critical to understanding pancreatic cellular biology and the pathophysiology of diabetes, and given the substantial differences to murine islets, access to the human islets is essential to translate findings from cell lines and mouse models. Therefore, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), continues to fund the IIDP, led by Drs. Joyce C. Niland and Carmella Evans-Molina, which affords ongoing coordination, information technology, and financial infrastructure, while offering innovative new biomaterials and integrated data to advance diabetes research. Read More ... Joyce C. Niland, Ph.D. , as Chair of the Department of Diabetes & Cancer Discovery Science at the Arthur Riggs Diabetes and Metabolism Research Institute at City of Hope, with Carmella Evans-Molina, M.D., Ph.D. , Director of the Indiana Diabetes Research Center at Indiana University (IU), its Islet and Physiology Core, and the IU Center for Diabetes and Metabolic Diseases, serve as Principal Investigators (PIs) for this program. Each bring their own necessary expertise to this vital program; Dr. Niland with over 40 years of experience in study coordination, informatics, biostatistics, and overseeing national/international coordinating centers and Dr. Evans-Molina as a physician scientist with expertise in human islet biology, specializing in clinical diabetes. The PIs are supported by a staff that have an impressive 150 years of experience in relevant programming, islet biology, regulatory, biostatistical and administrative expertise to assist in IIDP management. Islet Isolation Centers Islet isolation centers affiliated with IIDP Pivotal to IIDP’s mission is providing reliable, high quality resources to the research community from industry-leading Islet Isolation Centers (IICs). Each of the current 10 geographically diverse IICs was qualified based on: isolation team and center director credentials, working relationships with local as well as specific distant Organ Procurement Organizations with provision of consistent access to quality pancreata from donors that have been qualified for organ transplant, exemplary islet isolation history, and stable recipient satisfaction. The IIDP integrates this interactive group of IICs to maintain standardized protocols for the culture and shipping of human islets, both cultured and flash frozen. Most recently, the IIDP’s IICs offer an array of biospecimens from the same islet donor, including non-islet pancreatic tissue (ductal and acinar - fresh or frozen), serum, plasma, duodenal tissue, peripancreatic lymph nodes, spleen samples, and frozen pancreatic pieces. Each shipment is accompanied by comprehensive donor and isolation information, pre-shipment islet assessments for purity, viability, and islet quality ranking. The IIDP maintains an exclusive algorithm as part of a fair and equitable Islet Allocation System, which broadcasts the availability of human islets and non-islet biospecimens from each isolation center to subscribing investigators world-wide, tracks acceptance of tissue, and maintains feedback from the recipients. More information IIDP Phenotyping and Genotyping Initiatives The Human Islet Phenotyping Program (HIPP) was established per NIH mandate in the summer of 2016 and awarded to the Vanderbilt Diabetes Center after a peer-reviewed application process. The HIPP is managed by Dr. Marcela Brissova , also director of the Islet Procurement and Analysis Core at the Vanderbilt Diabetes Research and Training Center. The goal of the HIPP initiative is to provide standardized assessment of IIDP-contracted human islet preparations to understand the relationship between islet phenotypic features and key donor characteristics. HIPP generated data include purity, viability and potency assessments as well as hormone content and histological analysis of total preparation for endocrine vs exocrine cells and average composition of α, β, and δ cells through standardized assays. Real-time and complementary data are currently available to the IIDP-affiliated Islet Isolation Centers and Investigators through the IIDP-HIPP database In 2020, IIDP implemented the Human Islet Genotyping Initiative (HIGI) via a subaward to Stanford University, Palo Alto, CA with Dr. Anna Gloyn , a top tier genetics collaborator with expertise in diabetes, as director of this program. To provide a summary of the genetic characteristics of each donor, the HIGI will generate partitioned genetic risk (pGRS) scores for type 1 and type 2 diabetes. These pGRS are visualized on the IIDP Research Data Repository (RDR) , to provide an overview of the genetic contributions of a variety of physiological processes (e.g. islet cell, liver, adipose dysfunction) to each individual donor’s diabetes risk. HIGI also provides comprehensive, genomic ancestry data for each islet donor, which can also be found in the RDR. Investigators...